ReviewAPL bioengineering2026
Cardiac mechanotransduction from development to disease.
Review in APL bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mechanical cues control key aspects of cardiac structure formation and function from heart development through adult life. Because the heart is a pump, forces from muscle contraction and blood flow generate normal and shear stresses that, together with matrix stiffness, regulate cell fate, growth, and homeostasis through mechanotransduction. This review describes how mechanosensors in cardiomyocytes, endothelial cells, and fibroblasts, including integrins and stretch-activated ion channels, couple mechanical stimuli to their cellular responses. We outline pathways that translate force into key phenotypes relevant to morphogenesis, homeostasis, and disease progression, with emphasis on RhoA/ROCK, calcium, and Yes-associated protein (YAP) signaling. We also explain how elevated mechanical load driven by hypertension activates hypertrophic and fibrotic remodeling of cardiac chambers, particularly through transforming growth factor-β, integrins, YAP, and calcineurin signaling. Finally, we highlight emerging roles for mechanosensitive microRNAs in coordinating proliferation, metabolism, electrophysiology, and extracellular matrix dynamics in the heart. Since most, if not all, of these pathways are interconnected, a comprehensive understanding will require high-resolution maps of cardiac mechanical environments and clear links between defined stimuli and cell-type-specific responses. These insights will advance fundamental understanding and guide the development of more effective therapeutic strategies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.